Yunkang Group Limited (HKG:2325)
0.9100
-0.0100 (-1.09%)
Jan 30, 2026, 3:37 PM HKT
Yunkang Group Revenue
Yunkang Group had revenue of 313.22M CNY in the half year ending June 30, 2025, a decrease of -34.32%. This brings the company's revenue in the last twelve months to 645.16M, down -18.80% year-over-year. In the year 2024, Yunkang Group had annual revenue of 711.88M, down -20.15%.
Revenue (ttm)
645.16M CNY
Revenue Growth
-18.80%
P/S Ratio
0.75
Revenue / Employee
562.97K CNY
Employees
1,146
Market Cap
532.66M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 711.88M | -179.62M | -20.15% |
| Dec 31, 2023 | 891.50M | -2.86B | -76.27% |
| Dec 31, 2022 | 3.76B | 2.06B | 121.38% |
| Dec 31, 2021 | 1.70B | 496.42M | 41.36% |
| Dec 31, 2020 | 1.20B | 522.49M | 77.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WuXi XDC Cayman | 5.58B |
| Adicon Holdings | 2.98B |
| Kindstar Globalgene Technology | 998.42M |
| Biosino Bio-Technology and Science Incorporation | 246.61M |
| Mega Genomics | 171.61M |
| Guanze Medical Information Industry (Holding) | 161.70M |
| King International Investment | 77.50M |
| China Biotech Services Holdings | 76.93M |